Congress funds drug stockpiles to prevent shortages—but lets HHS pick winners

What it does

This bill creates a federal program where the Department of Health and Human Services awards contracts to drug manufacturers, ingredient suppliers, and distributors to maintain 6-month reserves of critical drugs and active pharmaceutical ingredients identified as having vulnerable supply chains. Participating companies receive government contracts to stockpile these reserves, implement production on HHS direction, and allow the government to redirect their reserves during public health emergencies. The bill authorizes $500 million for fiscal year 2026 and gives preference to domestic manufacturers.

Why we flagged it

The bill establishes a federal contracting mechanism to build and maintain strategic reserves of critical drugs and active pharmaceutical ingredients, with preference for domestic manufacturing. It is fundamentally a supply-chain security and public health preparedness measure, not a deregulation, tax provision, or commemorative act.

What the text implies

• The bill grants HHS broad discretion to determine which drugs are 'critical' and have 'vulnerable supply chains,' with minimal legislative definition—this creates significant administrative power to select beneficiary manufacturers without transparent criteria.
• Contracts may fund 'acquisition, construction, alteration, or renovation of non-federally owned establishments' (Section 4(2)), effectively subsidizing private manufacturing infrastructure with public funds; the public retains no ownership stake.
• The 6-month reserve requirement may incentivize manufacturers to maintain excess inventory indefinitely, shifting storage and carrying costs to the government while manufacturers capture contract payments.
• HHS can 'direct allocation' of reserves during emergencies and require transfer of ingredients to competing manufacturers, creating potential for political favoritism in allocation decisions and disputes over fair compensation.
• The bill requires biennial reporting to Congress but explicitly exempts information 'that does not compromise national security,' potentially allowing HHS to withhold details on which manufacturers received contracts and how much taxpayer money was spent.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill directly addresses drug shortage prevention and supply chain resilience for critical medications, reducing the risk of treatment disruptions during emergencies. Citizens gain access to more reliable drug supplies and faster emergency response capacity, though the mechanism relies on private manufacturers receiving government contracts—a mixed public-private arrangement that requires oversight to ensure taxpayer funds deliver genuine supply security rather than corporate subsidy.

Who stands to gain

• pharmaceutical manufacturers (contract holders)
• active pharmaceutical ingredient suppliers
• drug wholesalers and distributors
• construction and facility upgrade contractors

Named in the bill

Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Assistant Secretary for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Bristol Myers Squibb (BMY), Finmeccanica (FINMF), Merck (MHVYF), Fabrinet (FBIN), Johnson & Johnson (JNJ), Organisation for Economic Cooperation and Development (OECD)

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Jun 12, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 12, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 7 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,580,000 in lobbying spend. A filing names 8 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Gary Peters, the sponsor, reported $-186,100 in PAC receipts in the 2026 cycle.

• Phlow Corporation — $780,000 on 2 filings
• Association for Clinical Oncology — $600,000 on 2 filings
• Phlow Corporation — $180,000 on 2 filings
• American Association of Oral and Maxillofacial Surgeons — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.